Insilico Medicine · Primary source
Oct 12, 2026
Vertical + Enterprise · Public company · Growth
Insilico Medicine
✓ VerifiedInsilico Medicine matters because it is one of the most prominent efforts to turn AI for science into a repeatable drug-discovery business.
Hong KongFounded 2014No public API trackedWeekly review target
Editorial intelligence brief
Editorial focus
Released an open longevity-AI toolkit on September 17, 2026 comprising LongevityBench, five compact Longevity-LLMs, and the agentic Longevity Claw research platform alongside a Cell cover study.
Focus: AI-first drug discovery and biological research automation
Latest funding
$110M
Series E · source-backed
Tracked funding
$110M
Sum of itemized funding events
Latest valuation
Not tracked
No source-backed record
Latest revenue
Not tracked
Growth lifecycle position
Editorially verified updates
What changed
Released an open longevity-AI toolkit on September 17, 2026 comprising LongevityBench, five compact Longevity-LLMs, and the agentic Longevity Claw research platform alongside a Cell cover study.
External coverage of Insilico Medicine
Selected by relevance, date and publisher; grouped by story. External reporting is not independently verified by the map. Article dates are publisher timestamps supplied by the discovery feed; quieter profiles may show coverage up to 90 days old.
Last checked Oct 18, 2026.
Insilico Medicine · Primary source
Oct 11, 2026
Insilico Medicine · Primary source
Sep 30, 2026
Source-backed financial history
Funding and financial history
Funding, valuation, revenue, and debt are kept separate so unlike measurements are never presented as one trend.
Records
1
Sum of recorded funding
$110M
Coverage
partial
Partial history: earlier or intervening rounds may be missing. The sum covers only the announcements recorded here, not lifetime funding. Announced commitments may be paid over time; this is not a cash balance. Dates show announcements or first public reports, which can follow the investment itself.
One funding announcement recorded. More dated rounds are needed to show funding over time.
#1
Series E · $110M
Running tracked total: $110M
#1
Series E · $110M
Running tracked total: $110M
Sources and details for every recorded funding announcement, newest first.
Series E · $110M
$110M Series E.
Product surface
Products and model families
Recent models
Longevity-LLMsL-Qwen3.5-9B
Products
Pharma.AIRentosertibLongevityBenchLongevity Claw
Open weights
Yes
API access
No
Review target
Weekly
Market position
Lifecycle and strategic signals
Research
Preview
Growth
Deployment
Growth: Public access & scaling
Focus
AI-first drug discovery and biological research automation
Signals
ScienceBiotechScientific discovery
Taxonomy
Frontier LabsBiotechAI for scienceAI for science
Competitive context
Isomorphic LabsRecursionGenerate:Biomedicines
Infrastructure & distribution
Where Insilico Medicine sits in the AI stack
01
Model layer
2 tracked model families
02
Access layer
Self-hostable weights
03
Market layer
Vertical + Enterprise
Public product surface
Pharma.AIRentosertibLongevityBenchLongevity Claw
Stack signals
BiotechAI for scienceScienceScientific discovery
This section reflects publicly visible product and access signals. Undisclosed GPU, cloud, training, and data-center contracts are not inferred.
Evidence trail
Sources and corrections
Primary and public sources used to verify the structured company profile.
The Staticbreaker
Get the signal behind the week's AI changes.
The Staticbreaker turns launches, category shifts, and market noise into a concise editorial briefing.